Skip to content
Research Article Open access CC BY 4.0

Analysis of Dynamic Efficacy Profile of Corneal Cross-Linking: Role of Oxygen and Rate Constants in Type-I and II Processes

Jui-Teng Lin, Yi-Ze Lee

Ophthalmology Research: An International Journal · pp. 1–12 · Published 20 Dec 2021

10.9734/or/2021/v15i430217

Abstract

Purpose: To explore (theoretically) the key parameters and their influence on the time profiles of photosensitizer (riboflavin), free radicals, singlet oxygen, oxygen and the efficacy of corneal collagen crosslinking (CXL) in both type-I and oxygen-mediated type-II mechanisms, specially the role of oxygen and the initiator regeneration. Study Design: Numerical solutions of the rate equation of CXL. Place and Duration of Study: New Taipei City, Taiwan, between October, 2021 and November, 2021. Methodology: Coupled kinetic equations are derived and numerically solved under the quasi-steady state condition for the 2-pathway mechanisms of CXL. The key parameters explored include (bI, V, Q', K, K',Q,P) and their influence on the time profiles of photosensitizer (riboflavin, C), radicals (R), singlet oxygen(S), oxygen (X) and efficacy (E), parameters of (K,K',Q) define the relative strength of type-I and type-II process. The oxygen depletion profile, X(t), and the associated singlet oxygen, S(t), depend on the parameters of V, Q' and the initial value of oxygen. The coupling strength given by (bI) governs almost all profiles, where b is an effective absorption parameter and I is the UV light intensity. Results: Our numerical method for CXL dynamic profiles demonstrated the following important features: (i) Type-I and type-II co exit in CXL, in the presence of oxygen. However, there is no type-II when oxygen is depleted or in a condition without oxygen. (ii) Type-I with bimolecular termination, the radical R(t) is a function of [K'(bIgC)]0.5, leading to the steady-state efficacy given by a scaling law of 1/(bI)0.5, in contract to that of type-II which is almost independent to the light intensity. (iii) The depletion rate (2 to 5 minutes) of X(t) is much faster than that of C(t) (10 to 20 minutes), (iv) The pure type-II profile, has a transition point from straight line to saturating curve and matches the depletion point of singlet oxygen S(t). (v) Improved CXL efficacy of type-I and type-II may be achieved by external supply of photoinitiator (riboflavin) and oxygen, respectively.

Corneal crosslinking efficacy kinetic modeling oxygen riboflavin ultraviolet light.

References (21)

  1. 1 The Efficacy of Corneal Cross-Linking Shows a Sudden Decrease with Very High Intensity UV Light and Short Treatment Time [DOI]
  2. 2 Individualized Corneal Cross-linking With Riboflavin and UV-A in Ultrathin Corneas: The Sub400 Protocol [DOI]
  3. 3 An Algorithm to Predict the Biomechanical Stiffening Effect in Corneal Cross-linking [DOI]
  4. 4 Comparative Functional Outcomes After Corneal Crosslinking Using Standard, Accelerated, and Accelerated With Higher Total Fluence Protocols [DOI]
  5. 5 Riboflavin Concentrations at the Endothelium During Corneal Cross-Linking in Humans [DOI]
  6. 6 Customized corneal crosslinking for treatment of progressive keratoconus: Clinical and OCT outcomes using a transepithelial approach with supplemental oxygen [DOI]
  7. 7 Modeling the efficacy profiles of UV-light activated corneal collagen crosslinking [DOI]
  8. 8 Increased Biomechanical Efficacy of Corneal Cross-linking in Thin Corneas Due to Higher Oxygen Availability [DOI]
  9. 9 Toric Topographically Customized Transepithelial, Pulsed, Very High-Fluence, Higher Energy and Higher Riboflavin Concentration Collagen Cross-Linking in Keratoconus [DOI]
  10. 10 Oxygen Diffusion May Limit the Biomechanical Effectiveness of Iontophoresis-Assisted Transepithelial Corneal Cross-linking [DOI]
  11. 11 Iontophoresis Corneal Cross-linking With Enhanced Fluence and Pulsed UV-A Light: 3-Year Clinical Results [DOI]
  12. 12 Enhanced-Fluence Pulsed-Light Iontophoresis Corneal Cross-linking: 1-Year Morphological and Clinical Results [DOI]
  13. 13 A Critical Review for Synergic Kinetics and Strategies for Enhanced Photopolymerizations for 3D-Printing and Additive Manufacturing [DOI]
  14. 14 Photorefractive intrastromal corneal crosslinking for treatment of low myopia: clinical outcomes using the transepithelial approach with supplemental oxygen [DOI]
  15. 15 Optimization model for UV-Riboflavin corneal cross-linking [DOI]
  16. 16 Model for Optimization of the UV‐A/Riboflavin Strengthening (cross‐linking) of the Cornea: Percolation Threshold [DOI]
  17. 17 Corneal Collagen Cross-linking [DOI]
  18. 18 Critical Analysis of Corneal Cross-linking (Part-I): Formulas for Efficacy, Safety Dose, Minimum Thickness, Demarcation Line Depth and the Role of Oxygen [DOI]
  19. 19 Critical Analysis of Corneal Cross-linking (Part-II): Resolving the Controversial Issues (Theory versus Measurements) [DOI]
  20. 20 Influencing Factors Relating the Demarcation Line Depth and Efficacy of Corneal Crosslinking [DOI]
  21. 21 Modeling a new strategy and influencing factors for improved efficacy of accelerated corneal crosslinking [DOI]

Cited by 3

Proteomics Reveals Mechanisms of Delayed Keratoconus Progression: A Study of Corneas Following Two Light-Activated Crosslinking Treatments

Demi H. J. Vogels, Jurriaan Brekelmans, Ronny Mohren · Investigative Ophthalmology & Visual Science · 2025

Showing 1 of 3 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

60

Page views

0

PDF downloads

31

Outbound clicks

3

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.